Michael Barbella, Managing Editor01.09.23
Inscopix Inc. is expanding the market availability for its Inscopix Data Exploration, Analysis and Sharing (IDEAS) Platform to include individual labs, which allows academic researchers to improve the way they share, analyze, and organize neuroscience data.
Initially launched in December 2021 as enterprise-friendly solution, the cloud-based IDEAS Platform is billed as a first-of-its-kind turnkey solution for processing multimodal preclinical research data with its intuitive database solution and scalable compute infrastructure. Addressing one of the major roadblocks in current brain research efforts, IDEAS supports the organization, multi-modal integration, analysis and sharing of neuroscience imaging data and methods to accelerate basic research and catalyze progress towards the next-generation of neurotherapeutics.
“With the miniscope platform and other novel brain mapping tools, we now live in the age of big brain data, and the IDEAS Platform is the first integrated, multi-modal solution to address the needs of managing and analyzing brain data at scale,” Founder/CEO Kunal Ghosh, Ph.D., said.
The IDEAS Platform comes with several processing and analysis workflows ready to use—simplifying post-experiment data handling and enabling researchers in any lab to efficiently organize, analyze, and share results without relying on other tools. Workflows can be queued and batch executed, enabling analysis of rich multimodal datasets at scale without software or hardware requirements.
“The use of multiple data-rich technologies in the modern neuroscience lab also brings challenges like the siloed and cumbersome storage of data, lack of collaborative tools and the absence of readily shared and reproducible analysis methods,” Inscopix Chief Scientific Officer David Gray, Ph.D., said. “The new IDEAS Platform is an integrated, user-friendly solution that overcomes these challenges, and we’re now excited to offer it to both enterprise and individual research labs.”
Inscopix is a brain imaging platform company focused on decoding the mind to better understand and address all neurological disorders. The company is attempting to understand the way the brain works and is leveraging that knowledge to develop effective neurological treatments. With almost 200 peer-reviewed publications validating its brain circuitry imaging technology, Inscopix is empowering the neuroscience research community to advance science while bringing a new generation of transformational therapeutics to patients with difficult-to-treat brain disorders.
Initially launched in December 2021 as enterprise-friendly solution, the cloud-based IDEAS Platform is billed as a first-of-its-kind turnkey solution for processing multimodal preclinical research data with its intuitive database solution and scalable compute infrastructure. Addressing one of the major roadblocks in current brain research efforts, IDEAS supports the organization, multi-modal integration, analysis and sharing of neuroscience imaging data and methods to accelerate basic research and catalyze progress towards the next-generation of neurotherapeutics.
“With the miniscope platform and other novel brain mapping tools, we now live in the age of big brain data, and the IDEAS Platform is the first integrated, multi-modal solution to address the needs of managing and analyzing brain data at scale,” Founder/CEO Kunal Ghosh, Ph.D., said.
The IDEAS Platform comes with several processing and analysis workflows ready to use—simplifying post-experiment data handling and enabling researchers in any lab to efficiently organize, analyze, and share results without relying on other tools. Workflows can be queued and batch executed, enabling analysis of rich multimodal datasets at scale without software or hardware requirements.
“The use of multiple data-rich technologies in the modern neuroscience lab also brings challenges like the siloed and cumbersome storage of data, lack of collaborative tools and the absence of readily shared and reproducible analysis methods,” Inscopix Chief Scientific Officer David Gray, Ph.D., said. “The new IDEAS Platform is an integrated, user-friendly solution that overcomes these challenges, and we’re now excited to offer it to both enterprise and individual research labs.”
Inscopix is a brain imaging platform company focused on decoding the mind to better understand and address all neurological disorders. The company is attempting to understand the way the brain works and is leveraging that knowledge to develop effective neurological treatments. With almost 200 peer-reviewed publications validating its brain circuitry imaging technology, Inscopix is empowering the neuroscience research community to advance science while bringing a new generation of transformational therapeutics to patients with difficult-to-treat brain disorders.